About Infectious Diseases
Human beings are prone to various kinds of infections. Infectious diseases are caused by various pathogenic microorganisms such as bacteria, fungi, parasites, and
viruses. Antimicrobials are used to treat infections. They act by killing or resisting the growth of the microorganisms. They either act via the host defense system or
directly target the causative agent. Based on the target organism, antimicrobials can be classified into anti-bacterial, anti-viral, anti-fungal, and anti-parasitic
drugs.
Technavio's analysts forecast the infectious diseases market in US to grow at a CAGR of 3.37% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the infectious diseases market in US for the period 2015-2019. To calculate the market size, the
report considers revenue generated through the sales of drugs administered to treat infectious diseases caused by bacteria, viruses, fungi, and parasites.
The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the infectious diseases market in US. In addition, it discusses
the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that
are emerging in the market.
Technavio's report, Infectious Diseases Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. In addition,
it discusses the major drivers that influence the growth of the market, challenges faced by the vendors and the market at large, as well as the key trends that
contribute to the growth the market.
Key Vendors
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Pfizer
Other Prominent Vendors
• AbbVie
• Astellas Pharma
• AstraZeneca
• Bayer
• Bristol-Myers Squibb
• Chimerix Pharmaceuticals
• Cubist
• Eli Lilly
• Isis Pharmaceuticals
• Mitsubishi Tanabe Pharma
• Novartis
• Sanofi
• Vertex
Market Driver
• Rise in patient population
• For a full, detailed list, view our report
Market Challenge
• Generic erosion
• For a full, detailed list, view our report
Market Trend
• Emergence of IFN-free therapies
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.2.1 Market Penetration
06.2.2 Marketing Approvals
06.2.3 Patent Protection
06.2.4 Regulatory Designation
06.2.5 Orphan Drug Designation
06.2.6 WHO Recognition
06.2.7 Other Factors
06.3 Five Forces Analysis
07. Epidemiology
07.1 Viral Infections
07.2 Fungal Infections
07.3 Bacterial Infections
07.4 Parasitic Infections
08. Market Segmentation by Type of Drug
08.1 Anti-bacterial Drugs
08.1.1 Anti-bacterial Drugs Market in US
08.2 Anti-viral Drugs
08.2.1 Anti-viral Drugs Market in US
08.3 Anti-fungal Drugs
08.3.1 Anti-fungal Drugs Market in US
08.4 Anti-parasitic Drugs
08.4.1 Anti-parasitic Drugs Market in US
09. Market Segmentation by Route of Administration
09.1 Oral
09.2 Parenteral
09.3 Topical
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2014
17.2.1 Gilead Sciences
17.2.2 Johnson & Johnson
17.2.3 Merck
17.2.4 Pfizer
17.2.5 F. Hoffmann-La Roche
17.2.6 GlaxoSmithKline
17.3 Other and Future Prominent Vendors
18. Key Vendor Analysis
18.1 F. Hoffmann-La Roche Ltd.
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Information
18.1.8 SWOT Analysis
18.2 Gilead Sciences
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Geographical Segmentation by Revenue 2013
18.2.4 Recent Developments
18.2.5 SWOT Analysis
18.3 GlaxoSmithKline
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2014
18.3.4 Business Segmentation by Revenue 2013 and 2014
18.3.5 Geographical Segmentation by Revenue 2014
18.3.6 Business Strategy
18.3.7 Recent Developments
18.3.8 SWOT Analysis
18.4 Johnson & Johnson
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2014
18.4.4 Business Segmentation by Revenue 2013 and 2014
18.4.5 Geographical Segmentation by Revenue 2014
18.4.6 Business Strategy
18.4.7 Recent Developments
18.4.8 SWOT Analysis
18.5 Merck
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation by Revenue 2013
18.5.4 Business Segmentation by Revenue 2012 and 2013
18.5.5 Sales by Geography
18.5.6 Business Strategy
18.5.7 Key Developments
18.5.8 SWOT Analysis
18.6 Pfizer
18.6.1 Key Facts
18.6.2 Business Overview
18.6.3 Business Segmentation by Revenue 2014
18.6.4 Business Segmentation by Revenue 2013 and 2014
18.6.5 Geographical Segmentation by Revenue 2014
18.6.6 Business Strategy
18.6.7 Key Developments
18.6.8 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Infectious Diseases Market in US 2014-2019 ($ millions)
Exhibit 3: Segmentation of Infectious Diseases Market in US by Type of Drug
Exhibit 4: Segmentation of Infectious Diseases Market in US by Type of Drug 2014
Exhibit 5: Segmentation of Infectious Diseases Market in US by Type of Drug 2019
Exhibit 6: Types of Anti-bacterial Drug by Chemical Class
Exhibit 7: Anti-bacterial Drugs Market in US 2014-2019 ($ millions)
Exhibit 8: Types of Anti-viral Drug by Disease
Exhibit 9: Anti-viral Drugs Market in US 2014-2019 ($ millions)
Exhibit 10: Types of Anti-fungal Drugs by Chemical Class
Exhibit 11: Anti-fungal Drugs Market in US 2014-2019 ($ millions)
Exhibit 12: Anti-parasitic Drugs Market in US 2014-2019 ($ millions)
Exhibit 13: Segmentation of Infectious Diseases Market in US by Route of Administration
Exhibit 14: Segmentation of Infectious Diseases Market in US by Route of Administration 2014
Exhibit 15: Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
Exhibit 16: Gilead Sciences: Revenue of Truvada 2011-2014 ($ millions)
Exhibit 17: Gilead Sciences: Revenue of Atripla 2011-2014 ($ millions)
Exhibit 18: Gilead Sciences: Revenue of CompleraEviplera 2011-2014 ($ millions)
Exhibit 19: Gilead Sciences: Revenue of Viread 2011-2014 ($ millions)
Exhibit 20: Gilead Sciences: Revenue of Hepsera 2011-2013 ($ millions)
Exhibit 21: Gilead Sciences: Revenue of AmBisome 2011-2014 ($ millions)
Exhibit 22: Gilead Sciences: Percentage Share of Major Anti-infective Drugs 2014
Exhibit 23: Johnson & Johnson: YOY Revenue and Growth Rate of Anti-infective Drugs Segment 2011-2014 ($ millions)
Exhibit 24: Johnson & Johnson: Revenue of Key Anti-infective Drugs 2011-2014 ($ millions)
Exhibit 25: Merck: Key Anti-infective Drugs Portfolio
Exhibit 26: Merck: Share of Key Anti-infective Drugs 2014
Exhibit 27: Merck: Share of Key Anti-infective Drugs 2011-2014 ($ millions)
Exhibit 28: Merck: Sales Comparison of Key Anti-infective Drugs 2011-2014
Exhibit 29: Pfizer: Key Anti-infective Drugs Portfolio
Exhibit 30: Pfizer: Revenue of Key Anti-infective Drugs 2011-2014
Exhibit 31: Pfizer: Share of Key Anti-infective Drugs 2011-2014
Exhibit 32: F. Hoffmann-La Roche: Share of Major Anti-infective Drugs 2014
Exhibit 33: F. Hoffmann-La Roche: Revenue of Major Anti-infective Drugs 2012-2014 ($ millions)
Exhibit 34: GlaxoSmithKline: Key Anti-viral Drugs Portfolio
Exhibit 35: GlaxoSmithKline: Revenue of Key Anti-viral Drugs (Except ViiV Healthcare) 2014
Exhibit 36: GlaxoSmithKline: Key Anti-bacterial Drugs Portfolio
Exhibit 37: GlaxoSmithKline: Share of Augmentin in Anti-bacterial Drugs Segment 2014
Exhibit 38: GlaxoSmithKline: Key Anti-HIV Drugs Portfolio (ViiV Healthcare)
Exhibit 39: Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
Exhibit 40: F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
Exhibit 41: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
Exhibit 42: F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
Exhibit 43: Gilead Sciences: Geographical Segmentation by Revenue 2013
Exhibit 44: GlaxoSmithKline: Business Segmentation by Revenue 2014
Exhibit 45: GlaxoSmithKline: Business Segmentation by Revenue 2013 and 2014 ($ billion)
Exhibit 46: GlaxoSmithKline: Geographical Segmentation by Revenue 2014
Exhibit 47: Johnson & Johnson: Business Segmentation by Revenue 2014
Exhibit 48: Johnson & Johnson: Business Segmentation by Revenue 2013 and 2014 ($ billion)
Exhibit 49: Johnson & Johnson: Geographical Segmentation by Revenue 2014
Exhibit 50: Merck: Business Segmentation by Revenue 2013
Exhibit 51: Merck: Business Segmentation by Revenue 2012 and 2013 ($ billion)
Exhibit 52: Merck: Sales by Geography 2013
Exhibit 53: Pfizer: Business Segmentation by Revenue 2014
Exhibit 54: Pfizer: Business Segmentation by Revenue 2013 and 2014 ($ billion)
Exhibit 55: Pfizer: Geographical Segmentation by Revenue 2014
